ArticleBMC gastroenterology2025
Histological remission as a reliable predictor of clinical outcomes in patients with ulcerative colitis after conventional therapy: a 5-year analysis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding Remission of Long-Term Conditions Through Electronic Health Records: Scoping Review.Journal of medical Internet research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeHistological remission has emerged as a promising target that may improve long-term outcomes in patients with ulcerative colitis (UC). The aim of this study was to investigate correlations between clinical, endoscopic, and histological remissions and the predictive value of histological remission on long-term outcomes in patients with UC receiving conventional therapy.
methodsA retrospective study was conducted involving 183 patients with UC who underwent histological assessment between August 2004 and May 2018. Concordance among clinical, endoscopic, and histological remissions was evaluated using Fleiss kappa statistics. Cox multivariate regression analysis was performed to identify independent factors associated with long-term outcomes, including corticosteroid use, biologics requirements, hospitalization, and composite outcome of disease progression.
resultsAt baseline, 84.7% of patients were treated with 5-aminosalicylic acid and 15.3% with immunosuppressants. Histological remission exhibited fair agreement with endoscopic remission (κ = 0.280, 95%CI = 0.276–0.285, P < 0.001). Cox multivariate analysis revealed histological remission served as an independent protective factor against the need for corticosteroid (HR: 0.242, 95%CI = 0.087–0.675, P = 0.007), biologics requirements (HR 0.323, 95%CI = 0.114–0.914, P = 0.033), hospitalization for acute severe UC (HR 0.270, 95%CI = 0.083–0.875, P = 0.029), and disease progression (HR 0.340, 95%CI = 0.164–0.708, P = 0.004) over a median 5-year follow-up period.
conclusionHistological remission showed fair agreement with endoscopic remission and independently predicted better clinical outcomes, including reduced corticosteroid use, decreased biologics requirement, and lower rates of hospitalization and disease progression in patients with UC receiving conventional therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.